Matt Hoffman, Associate Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
Biogen Head Pens Open Letter Regarding Aducanumab Controversy in Alzheimer
July 23rd 2021Alfred Sandrock, MD, PhD, head of research and development, Biogen, has published an open letter to the Alzheimer community in an attempt to clarify “misinformation and misunderstanding” that has moved “outside the boundaries of legitimate scientific deliberation.”
FDA Commissioner Calls for Independent Review of Agency Interactions on Aducanumab
July 9th 2021Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."
Love and a Lab Coat: One Couple’s Quest to Treat Alzheimer Disease
June 20th 2021Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.
Managing the Intricacies and Age-Specific Challenges of Pediatric Multiple Sclerosis
June 17th 2021Two experts in pediatric MS care, Lauren B. Krupp, MD, and Tanuja Chitnis, MD, offer tips and insight on the diagnosis of the disease and the specific challenges faced by patients stemming from their own clinical experience.
Aducanumab for Alzheimer Disease: Landmark Moment or False Hope for Patients?
June 8th 2021Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.